Omalizumab (OMZ) is a monoclonal antibody that recognizes the Cε3 domain of IgE with high affinity, blocking the latter′s interaction with the specific FcεRI receptor, reducing not only serum IgE levels but also the level of eosinophilia [70]. This evidence concerns the gene IGHE and Increased total eosinophil count.